{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:09:01Z","timestamp":1792786141409,"version":"4.5.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"name":"National Institute on Drug Abuse","award":["K08DA061258"],"award-info":[{"award-number":["K08DA061258"]}],"id":[{"id":"https:\/\/ror.org\/00fq5cm18","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institute of Mental Health","award":["R25 MH112473"],"award-info":[{"award-number":["R25 MH112473"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>With rising obesity rates and increasing glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, understanding perinatal prescribing patterns is important. We conducted a retrospective cohort study to examine semaglutide and tirzepatide prescribing among pregnant patients in the United States from 2019 to 2024. We analyzed prescriptions during the year before and after delivery, grouping deliveries into 6-month periods and applying segmented linear regression with data-driven change-point detection to identify prescribing-trend shifts. Prevalence of GLP-1 RA prescribing increased from 0.2 to 6.4 per 1,000 deliveries predelivery and from 0.3 to 14.6 per 1,000 deliveries postdelivery, with significant prescribing change points indicating accelerated prescribing in June 2022 for the predelivery period and in March 2021 for the postdelivery period. These findings suggest rapid adoption of GLP-1 RAs in the perinatal period and underscore the need for evidence-based safety data for these medications.<\/jats:p>","DOI":"10.1097\/aog.0000000000006161","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:00:20Z","timestamp":1767909620000},"page":"290-292","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons"],"prefix":"10.1097","volume":"147","author":[{"given":"Chloe","family":"Lessard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Cary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"In","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Steinle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binx Y.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita S.","family":"Kablinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Grucza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget M.","family":"Galati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie C.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Young","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"R1-20260930","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2024.18219","article-title":"GLP-1 medication use for type 2 diabetes has soared","volume":"332","author":"Hegland","year":"2024","journal-title":"JAMA"},{"key":"R2-20260930","first-page":"2401","article-title":"Global trends in prevalence of maternal overweight and obesity: a systematic review and meta-analysis of routinely collected data retrospective cohorts","volume":"9","author":"Kent","year":"2024","journal-title":"Int J Popul Data Sci"},{"key":"R3-20260930","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/AOG.0000000000004395","article-title":"Obesity in pregnancy. ACOG Practice Bulletin No. 230. American College of Obstetricians and Gynecologists","volume":"137","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R4-20260930","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajog.2024.08.024","article-title":"Glucagon-like peptide-1 receptor agonist use in pregnancy: a review","volume":"232","author":"Drummond","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"R5-20260930","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"Jama Intern Med"},{"key":"R6-20260930","doi-asserted-by":"crossref","first-page":"116.e1","DOI":"10.1016\/j.ajog.2025.01.019","article-title":"Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes","volume":"233","author":"Imbroane","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"R7-20260930","first-page":"38","article-title":"Births: provisional data for 2024","author":"Hamilton","year":"2025","journal-title":"Vital Statistics Rapid Release"},{"key":"R8-20260930","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1186\/s12884-024-07007-8","article-title":"Effects of a behavioral intervention on physical activity, diet, and health-related quality of life in postpartum women with elevated weight: results of the HIPP randomized controlled trial","volume":"24","author":"Wilcox","year":"2024","journal-title":"BMC Pregnancy Childbirth"},{"key":"R9-20260930","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3390\/jcm10091891","article-title":"Reducing postpartum weight retention: a review of the implementation challenges of postpartum lifestyle interventions","volume":"10","author":"Makama","year":"2021","journal-title":"J Clin Med"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:00:30Z","timestamp":1790780430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006161","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"2025-09-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}